These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 15703363)

  • 1. Ascending multiple-dose pharmacokinetics of viramidine, a prodrug of ribavirin, in adult subjects with compensated hepatitis C infection.
    Aora S; Xu C; Teng A; Peterson J; Yeh LT; Gish R; Lau D; Rossi S; Lin CC
    J Clin Pharmacol; 2005 Mar; 45(3):275-85. PubMed ID: 15703363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and safety of viramidine, a prodrug of ribavirin, in healthy volunteers.
    Lin CC; Philips L; Xu C; Yeh LT
    J Clin Pharmacol; 2004 Mar; 44(3):265-75. PubMed ID: 14973309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Absorption, metabolism, and excretion of [14C]viramidine in humans.
    Lin CC; Xu C; Zhu N; Yeh LT
    Antimicrob Agents Chemother; 2006 Jul; 50(7):2368-73. PubMed ID: 16801414
    [TBL] [Abstract][Full Text] [Related]  

  • 4. LC-MS/MS method for simultaneous determination of viramidine and ribavirin levels in monkey red blood cells.
    Yeh LT; Nguyen M; Dadgostari S; Bu W; Lin CC
    J Pharm Biomed Anal; 2007 Feb; 43(3):1057-64. PubMed ID: 17029670
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Viramidine, a prodrug of ribavirin, shows better liver-targeting properties and safety profiles than ribavirin in animals.
    Lin CC; Yeh LT; Vitarella D; Hong Z
    Antivir Chem Chemother; 2003 May; 14(3):145-52. PubMed ID: 14521331
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitive and specific LC-MS/MS method for the simultaneous measurements of viramidine and ribavirin in human plasma.
    Liu Y; Xu C; Yan R; Lim C; Yeh LT; Lin CC
    J Chromatogr B Analyt Technol Biomed Life Sci; 2006 Feb; 832(1):17-23. PubMed ID: 16455313
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Absence of clinically relevant pharmacokinetic interaction between ribavirin and tenofovir in healthy subjects.
    Ramanathan S; Cheng A; Mittan A; Ebrahimi R; Kearney BP
    J Clin Pharmacol; 2006 May; 46(5):559-66. PubMed ID: 16638739
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conversion of viramidine to ribavirin in vivo by adenosine deaminase and its inhibition by 2'-deoxycoformycin.
    Wu JZ; Yeh LT; Lin CC; Hong Z
    Antivir Chem Chemother; 2006; 17(1):33-9. PubMed ID: 16542004
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics and metabolism of [14C]viramidine in rats and cynomolgus monkeys.
    Lin CC; Luu K; Lourenco D; Yeh LT
    Antimicrob Agents Chemother; 2003 Aug; 47(8):2458-63. PubMed ID: 12878505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Disposition and metabolic profiles of [14C]viramidine and [14C]ribavirin in rat and monkey red blood cells and liver.
    Lin CC; Lourenco D; Xu G; Yeh LT
    Antimicrob Agents Chemother; 2004 May; 48(5):1872-5. PubMed ID: 15105147
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo influenza virus-inhibitory effects of viramidine.
    Sidwell RW; Bailey KW; Wong MH; Barnard DL; Smee DF
    Antiviral Res; 2005 Oct; 68(1):10-7. PubMed ID: 16087250
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
    Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
    Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ribavirin levels in post liver transplant patients treated for recurrent hepatitis C viral infection.
    Jain A; Vekatramanan R; Yelochan B; Kashyap R; Marcos A; Fung J
    Transplant Proc; 2005 Sep; 37(7):3190-6. PubMed ID: 16213346
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of ribavirin, levovirin and viramidine on liver toxicological gene expression in rats.
    Fang C; Srivastava P; Lin CC
    J Appl Toxicol; 2003; 23(6):453-9. PubMed ID: 14635270
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dual-action mechanism of viramidine functioning as a prodrug and as a catabolic inhibitor for ribavirin.
    Wu JZ; Larson G; Hong Z
    Antimicrob Agents Chemother; 2004 Oct; 48(10):4006-8. PubMed ID: 15388466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and evaluation of a new phosphorylated ribavirin prodrug.
    Dong SD; Lin CC; Schroeder M
    Antiviral Res; 2013 Jul; 99(1):18-26. PubMed ID: 23624267
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and safety of single-dose ribavirin in patients with chronic renal impairment.
    Gupta SK; Kantesaria B; Glue P
    Drug Discov Ther; 2013 Aug; 7(4):158-63. PubMed ID: 24071578
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Blood ribavirin concentration in high-dose ribavirin for adenovirus-induced haemorrhagic cystitis - a case report.
    Homma M; Inoue Y; Hasegawa Y; Kojima H; Kohda Y
    J Clin Pharm Ther; 2008 Feb; 33(1):75-8. PubMed ID: 18211620
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exploring the influence of renal dysfunction on the pharmacokinetics of ribavirin after oral and intravenous dosing.
    K Gupta S; Kantesaria B; Glue P
    Drug Discov Ther; 2014 Apr; 8(2):89-95. PubMed ID: 24815584
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Taribavirin in the treatment of hepatitis C.
    Deming P; Arora S
    Expert Opin Investig Drugs; 2011 Oct; 20(10):1435-43. PubMed ID: 21854301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.